NextCure (NXTC) Insider Stephen Webster Buys 2,340 Shares

Stephen Webster made a move in NXTC by purchasing 2,340 shares on June 18, 2026. The transaction did not specify a price, but the shares traded at $1.75 on Tuesday. This activity is part of a broader pattern of insider buys at NXTC on the same date.

Other Institutional Activity in NXTC

Several institutional investors have adjusted their positions in NXTC recently. Squadron Capital Management LLC increased its holdings by 28,034 shares, ending with 265,000 shares valued at about $2,830,200, marking an 11.8% increase. Affinity Asset Advisors, LLC, however, trimmed its stake by 5,468 shares to hold 241,826 shares worth approximately $2,582,702, a 2.2% decrease. Meanwhile, Ikarian Capital, LLC and Sofinnova Investments, Inc. maintained their positions with no change, holding 238,303 and 222,654 shares respectively. Vanguard Capital Management LLC opened a new position with 160,473 shares valued at $1,688,176.

NextCure, Inc. Stock Down 71.4%

NXTC shares were trading at $1.75 on Tuesday. NXTC is seeing varied institutional interest, which could be reflective of broader market dynamics and investor sentiment.

Insider Buying and Selling at NextCure, Inc.

On June 18, 2026, several insiders, including Ellen Feigal, Anne Elizabeth Borgman, Elaine Jones, John Houston, Stephen Webster, and David Kabakoff, each purchased 2,340 shares of NXTC, except for Kabakoff who bought 3,510 shares. None of these transactions were part of a pre-planned trading program.

Analysts Set New Price Targets

On May 11, 2026, Lucid Capital Markets initiated coverage on NXTC with a 'buy' rating and a $25 price target. Earlier, on November 7, 2025, Ladenburg Thalmann upgraded NXTC to a 'buy' with an $18 target. Piper Sandler and HC Wainwright & Co. have maintained their 'buy' ratings with targets between $3 and $15.

About NXTC

NXTC is a company engaged in developing innovative therapies. It focuses on advancing treatments for various medical conditions, aiming to address unmet needs in healthcare. The company is at the forefront of research and development in its sector, striving to bring new solutions to market.

Bottom Line

Stephen Webster's recent purchase of NXTC shares is part of a wave of insider buying, which can be a positive signal for investors. With multiple institutional investors adjusting their positions and analysts maintaining optimistic price targets, NXTC is a stock to watch. Keep in mind that these insider and institutional activities reflect past decisions and do not necessarily predict future performance.